new study published annals internal medicine demonstrated risperidone risperdal effective reducing depressive symptoms people responded prior course antidepressant treatment effective marketing angle tie invega let find effective people responding current antidepressant assigned receive risperidone placebo add current antidepressant treatment average people taking risperdal improved points hamilton depression rating scale ham relative people taking placebo look scale tell me think points meaningful difference decide yes difference statistically significant sample size contains people spilt two groups common small difference statistically significant similarly small cases moderate statistically significant differences found measures assessing overall mental health disability life satisfaction results terms response treatment i getting better remission significant symptoms depression little encouraging overwhelmingly sum risperidone worked better placebo add antidepressant treatment small moderate margin far good lies damned lies statistics two quotes discussion section study risperidone augmentation offered statistically significant benefit multiple measures within week magnitude benefit appeared increase steadily throughout study findings suggest risperidone augmentation well tolerated beneficial effects early course treatment among patients respond initial therapy investigators reported early symptom improvement first week therapy may predict eventualremission key ultimate treatment objective stickler details end week average patient risperdal points better ham see compared average patient placebo yes statistically significant pretty close meaningless oh week difference shrunk points longer statistically significant magnitude benefit appear increase steadily throughout study benefit decreased week week benefit risperidone placebo improve measly points ham week questionably meaningful points week sure steadily increasing benefit worthy much mention enter invega another piece discussion although evaluated trial new medication closely related risperidone extended release paliperidone hypothetical advantages related metabolism delivery system including reduced serum fluctuation reduced peak exposure fewer cytochrome p related drug drug interactionswith widely used antidepressants awesome i hoping mention invega paliperidone son risperdal i disappointed likely know invega patent extender janssen generic risperidone soon make branded risperdal clearly attempt link present study modestly positive results invega bet life savings janssen reps pounding doors attempting convince docs invega like risperdal better trumped advantages include hypothetical advantages mentioned study published highly respected journal goes show product like invega works antidepressant invega gives efficacy risperdal new improved formulation note peer reviewers actually obligated run marketing tripe janssen single reference cited support hypothetical advantages invega one future i think statements lack supporting data excluded journal supposed science marketing right key opinion leaders go previous trial examined risperidone antidepressant generally finding drug ineffective though one look closely notice use tricky statistics trial prior trial also noteworthy authorship line apparently included people whose contributions study seemed minimal addition order authors switched around suspicious ways data moved around presented conferences published present study key opinion leaders nowhere found authorship line i know people janssen read prior posts regarding prior study perhaps learned someone watching adding authors sake marketing lending veneer independence credibility industry funded study may well become public knowledge making look like used car salespeople case i appreciate academic authors thrown authorship line means boosting credibility present study i snort couple seroquel deal marketing trickery rumor seroquel pretty good high